GNFT

TGFTX1

Psoriasis or Respiratory Conditions

Stage (next event)

Expected Date

Pre-Clinical

TBD

Catalyst Info & Data Links

TITLE: TGFTX1 for Psoriasis or Respiratory Conditions (Pre-clinical)


WHAT IS THE NEXT CATALYST EVENT?

  • TBD


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD


PRIOR DATA
PRESS RELEASES


PUBLICATIONS


MECHANISM OF ACTION

  • Our TGFTX1 preclinical program is focused on the discovery and development of innovative drug candidates targeting RORγt, a key nuclear receptor that directs IL-17 mediated immunity. In particular, we focus on treating psoriasis or respiratory conditions such as neutrophilic asthma, chronic obstructive pulmonary disease, or COPD, and the asthma-COPD overlap syndrome (ACOS).

Updated by MV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon